As part of its Year-End sales metrics provided this Wednesday ahead of its Investor Day, the company also raised its FY24 revenue view to $995M-$1.0B from $985M-$995M. CFO James Lucania stated: “This strong fourth quarter sales performance provides management the ability to raise and narrow guidance for fiscal 2024, maintain and reaffirm our fiscal 2025 outlook and layout intermediate profit goals despite declining benchmark treasury rates over the past three months. Our goal is to double non-GAAP net income per share over the next three fiscal years as HSA cash yields continue to rise and margins continue to expand.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HQY:
- HealthEquity Reports Year-End Sales Metrics
- HealthEquity price target raised to $93 from $85 at BofA
- HealthEquity Recognized by Glassdoor as a Top U.S. Workplace for 2024
- Wells says key metrics tracking ahead as HealthEquity provides sales outlook
- HealthEquity Announces Year-End HSA Sales Outlook; Presentation at J.P. Morgan Healthcare Conference; Investor Day
